Menu
Enrolling by invitation NCT05752032

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Observational Osteoarthritis, Knee

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: ICM-203, Placebo.
Who it may be relevant to
Registry conditions: Osteoarthritis, Knee. Basic parameters: 50 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Australia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This is an observational study of the long term safety and efficacy of ICM-203.

Detailed description

Subjects who have received ICM-203 or matching placebo from ICM-203 clinical studies will be enrolled. Subjects will be contacted annually to collect safety and efficacy outcomes until 5 years after the last dose of ICM-203 or placebo.

Interventions

  • Genetic ICM-203
    Long term follow-up
  • Drug Placebo
    Long term follow-up

Primary outcome measures

  • Incidence of delayed adverse events [Time frame: Up to 5 years]
Secondary outcome measures (5)
  • Knee pain [Time frame: Up to 3 years]
  • Knee function [Time frame: Up to 3 years]
  • Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS) [Time frame: Up to 3 years]
  • Joint space width [Time frame: Up to 3 years]
  • Incidence of total knee replacement [Time frame: Up to 5 years]

Eligibility criteria

Inclusion criteria

  • Previous receipt of ICM-203 or matching placebo

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Other

Study locations

Australia · 2 centers
  • Royal Adelaide Hospital — Adelaide
  • Barwon Health — Geelong

Identifiers

NCT: NCT05752032 · ICM 20-1002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗